The DOI matches its Crossref record.
VEGF-D Is the Strongest Angiogenic and Lymphangiogenic Effector Among VEGFs Delivered Into Skeletal Muscle via Adenoviruses
Abstract
Optimal angiogenic and lymphangiogenic gene therapy requires knowledge of the best growth factors for each purpose. We studied the therapeutic potential of human vascular endothelial growth factor (VEGF) family members VEGF-A, VEGF-B, VEGF-C, and VEGF-D as well as a VEGFR-3–specific mutant (VEGF-C 156S ) using adenoviral gene transfer in rabbit hindlimb skeletal muscle. The significance of proteolytic processing of VEGF-D was explored using adenoviruses encoding either full-length or mature (ΔNΔC) VEGF-D. Adenoviruses expressing potent VEGFR-2 ligands, VEGF-A and VEGF-D ΔNΔC , induced the strongest angiogenesis and vascular permeability effects as assessed by capillary vessel and perfusion measurements, modified Miles assay, and MRI. The most significant feature of angiogenesis induced by both VEGF-A and VEGF-D ΔNΔC was a remarkable enlargement of microvessels with efficient recruitment of pericytes suggesting formation of arterioles or venules. VEGF-A also moderately increased capillary density and created glomeruloid bodies, clusters of tortuous vessels, whereas VEGF-D ΔNΔC –induced angiogenesis was more diffuse. Vascular smooth muscle cell proliferation occurred in regions with increased plasma protein extravasation, indicating that arteriogenesis may be promoted by VEGF-A and VEGF-D ΔNΔC . Full-length VEGF-C and VEGF-D induced predominantly and the selective VEGFR-3 ligand VEGF-C 156S exclusively lymphangiogenesis. Unlike angiogenesis, lymphangiogenesis was not dependent on nitric oxide. The VEGFR-1 ligand VEGF-B did not promote either angiogenesis or lymphangiogenesis. Finally, we found a positive correlation between capillary size and vascular permeability. This study compares, for the first time, angiogenesis and lymphangiogenesis induced by gene transfer of different human VEGFs, and shows that VEGF-D is the most potent member when delivered via an adenoviral vector into skeletal muscle.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lymphangiogenesis in development and human disease
Alitalo, K., Tammela, T., & Petrova, T. V. (2005) · Nature · doi:10.1038/nature04480 · Cited by 1,285
Self-citationThe lymphatic vasculature in disease
Alitalo, K. (2011) · Nature Medicine · doi:10.1038/nm.2545 · Cited by 962
Self-citationBiology of vascular endothelial growth factors
Roy, H., Bhardwaj, S., & Ylä-Herttuala, S. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.03.087 · Cited by 537
Vascular endothelial growth factor B controls endothelial fatty acid uptake
Hagberg, C. E., Falkevall, A., Wang, X., Larsson, E., Huusko, J., Nilsson, I., van Meeteren, L. A., Samen, E., Lu, L., Vanwildemeersch, M., et al. (2010) · Nature · doi:10.1038/nature08945 · Cited by 512
Vascular Endothelial Growth Factors
Ylä-Herttuala, S., Rissanen, T. T., Vajanto, I., & Hartikainen, J. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.053 · Cited by 480
Self-citation
Metadata
- Authors
- Rissanen, T. T., Markkanen, J. E., Gruchala, M., Heikura, T., Puranen, A., Kettunen, M. I., Kholová, I., Kauppinen, R. A., Achen, M. G., Stacker, S. A., Alitalo, K., & Ylä-Herttuala, S.
- Venue
- Circulation Research
- Published
- 2003-05-30
- Volume
- 92
- Issue
- 10
- Pages
- 1098-1106
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2149749420
- Cited by
- 442
- References
- 0
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: VEGF-D Is the Strongest Angiogenic and Lymphangiogenic Effector Among VEGFs Delivered Into Skeletal Muscle via Adenoviruses. https://app.cochat.ai/papers/10.1161/01.res.0000073584.46059.e3
- The paper
- Rissanen, T. T., Markkanen, J. E., Gruchala, M., Heikura, T., Puranen, A., Kettunen, M. I., Kholová, I., Kauppinen, R. A., Achen, M. G., Stacker, S. A., Alitalo, K., & Ylä-Herttuala, S. (2003). VEGF-D Is the Strongest Angiogenic and Lymphangiogenic Effector Among VEGFs Delivered Into Skeletal Muscle via Adenoviruses. Circulation Research. https://doi.org/10.1161/01.res.0000073584.46059.e3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.